MICHAEL ROH, M.D.
Ophthalmology Physician · HUNTINGTON BEACH, CA
Individual Active NPI 1386684629
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 904 | 37,516 | $4,440,248 | $2,640,059 | $2,077,016 |
| 2023 | 812 | 27,703 | $3,481,664 | $2,166,457 | $1,697,594 |
| 2022 | 864 | 10,382 | $2,760,725 | $1,763,491 | $1,376,489 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J2777 | Injection, faricimab-svoa, 0.1 mg | 29,040 | $34 | $27 |
| 92134 | Imaging of retina | 2,078 | $45 | $33 |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | 1,395 | $147 | $117 |
| 67028 | Injection of drug into eye | 1,200 | $132 | $101 |
| 92012 | Established patient problem focused exam of visual system | 894 | $99 | $71 |
| J0177 | Injection, aflibercept hd, 1 mg | 720 | $331 | $264 |
| J0178 | Injection, aflibercept, 1 mg | 642 | $825 | $657 |
| 92014 | Established patient complete exam of visual system | 457 | $139 | $98 |
| J7999 | Compounded drug, not otherwise classified | 286 | $92 | $73 |
| J2778 | Injection, ranibizumab, 0.1 mg | 161 | $161 | $128 |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 148 | $211 | $168 |
| 92004 | New patient complete exam of visual system | 128 | $164 | $121 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Ophthalmology Physician | 207W00000X | ✓ | A94706 | CA |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Ophthalmology Physician providers in California
- NPI 1033174040
- NPI 1811427875
- NPI 1124535406
- NPI 1568714079
- NPI 1033533195
- NPI 1881224210
- NPI 1396913315
- NPI 1033122957
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.